Stem cell replacement therapy as a potential treatment for SCA1 disease

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant neurodegenerative disorder caused by expansion of CAG trinucleotide repeats in the ataxin-1 gene and is characterized by cerebellar ataxia and progressive motor deterioration. The ataxin-1 protein is involved in transcription and RNA processing. SCA1 pathogenesis appears to be related to a gain-of-function effect that is caused by toxic mutant ataxin-1-derived aggregates or cellular dysfunction through an abnormal interaction between mutated and normal proteins. Recent studies have clarified the molecular mechanisms of SCA1 pathogenesis, which provide direction for future treatments. Therapeutic hope has come from observations including the reduction of aggregates and alleviation of the pathogenic phenotype by the application of potent inhibitors and RNA interference. However, no treatment is currently available for SCA1 disease. In this chapter, we discuss the potential of stem cells as a therapeutic approach to SCA1.

Original languageEnglish
Title of host publicationAtaxia: Causes, Symptoms and Treatment
PublisherNova Science Publishers, Inc.
Pages177-188
Number of pages12
ISBN (Print)9781619428676
Publication statusPublished - 2012 Feb 1

Fingerprint

Spinocerebellar Ataxias
Cell- and Tissue-Based Therapy
Stem Cells
Trinucleotide Repeat Expansion
Therapeutics
Cerebellar Ataxia
Poisons
RNA Interference
Neurodegenerative Diseases
RNA
Phenotype
Genes
Ataxin-1
Proteins

Keywords

  • Aggregates
  • Cell replacement therapy
  • Polyglutamine
  • SCA1 disease
  • Stem cells

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

Hong, S., & Kang, S. M. (2012). Stem cell replacement therapy as a potential treatment for SCA1 disease. In Ataxia: Causes, Symptoms and Treatment (pp. 177-188). Nova Science Publishers, Inc..

Stem cell replacement therapy as a potential treatment for SCA1 disease. / Hong, Sunghoi; Kang, Seong Man.

Ataxia: Causes, Symptoms and Treatment. Nova Science Publishers, Inc., 2012. p. 177-188.

Research output: Chapter in Book/Report/Conference proceedingChapter

Hong, S & Kang, SM 2012, Stem cell replacement therapy as a potential treatment for SCA1 disease. in Ataxia: Causes, Symptoms and Treatment. Nova Science Publishers, Inc., pp. 177-188.
Hong S, Kang SM. Stem cell replacement therapy as a potential treatment for SCA1 disease. In Ataxia: Causes, Symptoms and Treatment. Nova Science Publishers, Inc. 2012. p. 177-188
Hong, Sunghoi ; Kang, Seong Man. / Stem cell replacement therapy as a potential treatment for SCA1 disease. Ataxia: Causes, Symptoms and Treatment. Nova Science Publishers, Inc., 2012. pp. 177-188
@inbook{119934bd5ad54c87986afc7372525d9f,
title = "Stem cell replacement therapy as a potential treatment for SCA1 disease",
abstract = "Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant neurodegenerative disorder caused by expansion of CAG trinucleotide repeats in the ataxin-1 gene and is characterized by cerebellar ataxia and progressive motor deterioration. The ataxin-1 protein is involved in transcription and RNA processing. SCA1 pathogenesis appears to be related to a gain-of-function effect that is caused by toxic mutant ataxin-1-derived aggregates or cellular dysfunction through an abnormal interaction between mutated and normal proteins. Recent studies have clarified the molecular mechanisms of SCA1 pathogenesis, which provide direction for future treatments. Therapeutic hope has come from observations including the reduction of aggregates and alleviation of the pathogenic phenotype by the application of potent inhibitors and RNA interference. However, no treatment is currently available for SCA1 disease. In this chapter, we discuss the potential of stem cells as a therapeutic approach to SCA1.",
keywords = "Aggregates, Cell replacement therapy, Polyglutamine, SCA1 disease, Stem cells",
author = "Sunghoi Hong and Kang, {Seong Man}",
year = "2012",
month = "2",
day = "1",
language = "English",
isbn = "9781619428676",
pages = "177--188",
booktitle = "Ataxia: Causes, Symptoms and Treatment",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Stem cell replacement therapy as a potential treatment for SCA1 disease

AU - Hong, Sunghoi

AU - Kang, Seong Man

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant neurodegenerative disorder caused by expansion of CAG trinucleotide repeats in the ataxin-1 gene and is characterized by cerebellar ataxia and progressive motor deterioration. The ataxin-1 protein is involved in transcription and RNA processing. SCA1 pathogenesis appears to be related to a gain-of-function effect that is caused by toxic mutant ataxin-1-derived aggregates or cellular dysfunction through an abnormal interaction between mutated and normal proteins. Recent studies have clarified the molecular mechanisms of SCA1 pathogenesis, which provide direction for future treatments. Therapeutic hope has come from observations including the reduction of aggregates and alleviation of the pathogenic phenotype by the application of potent inhibitors and RNA interference. However, no treatment is currently available for SCA1 disease. In this chapter, we discuss the potential of stem cells as a therapeutic approach to SCA1.

AB - Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant neurodegenerative disorder caused by expansion of CAG trinucleotide repeats in the ataxin-1 gene and is characterized by cerebellar ataxia and progressive motor deterioration. The ataxin-1 protein is involved in transcription and RNA processing. SCA1 pathogenesis appears to be related to a gain-of-function effect that is caused by toxic mutant ataxin-1-derived aggregates or cellular dysfunction through an abnormal interaction between mutated and normal proteins. Recent studies have clarified the molecular mechanisms of SCA1 pathogenesis, which provide direction for future treatments. Therapeutic hope has come from observations including the reduction of aggregates and alleviation of the pathogenic phenotype by the application of potent inhibitors and RNA interference. However, no treatment is currently available for SCA1 disease. In this chapter, we discuss the potential of stem cells as a therapeutic approach to SCA1.

KW - Aggregates

KW - Cell replacement therapy

KW - Polyglutamine

KW - SCA1 disease

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=84891969084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891969084&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84891969084

SN - 9781619428676

SP - 177

EP - 188

BT - Ataxia: Causes, Symptoms and Treatment

PB - Nova Science Publishers, Inc.

ER -